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ABSTRACT
In Finland, the number of problem opioid and amphetamine users lies between 
18,000 and 30,000, whereby only 20% receive treatment for their dependence. 
Annually illicit or medicinal drugs are found in the blood samples of more than 
6,000 drivers, and approximately 500 fatal poisonings result from drugs. Drug 
testing attempts to unravel the role of psychoactive substances—whether used for 
therapeutic purposes or abused—under various circumstances. Such occasions 
requiring drug testing include treatment for drug users and poisoned patients, 
patient compliance, driving under the influence of drugs, and post-mortem 
toxicology. Although various techniques are available for the determination of a 
range of psychoactive substances, few methods provide cost-efficient means to 
detect the wide range of abused drugs. Many conventional methods remain too 
narrow in scope, complicated, or lead to false-positive or false-negative results. 
A current challenge for drug testing laboratories is the wide and changing panel 
of abused drugs. New psychoactive substances (NPS) continually emerge on the 
drug scene, requiring analytical methods not necessary ten years ago. These 
chemically diverse substances typically remain undetected by common drug testing 
methods, whereby reference standards are often insufficiently available further 
impeding method development. NPS are manufactured predominantly in the Far 
East and intended to mimic the effects of conventional drugs, while circumventing 
narcotic laws and drug testing. Due to their rapid appearance and disappearance, 
NPS display a challenging group of analytes to detect. 
This thesis focuses on three main objectives: first, to develop and validate a 
multi-analyte urine drug testing method exhibiting a high sensitivity and a high 
substance identification power; second, to compare the new method to two 
established approaches for drug testing; and third, to apply the new method to urine 
samples from drug abusers to assess drug abuse patterns in various groups of 
patients. Special attention is paid to the detection and prevalence of NPS. 
A comprehensive drug testing method based on ultra-high performance liquid 
chromatography/high-resolution quadrupole time-of-flight mass spectrometry 
(UHPLC-HR-QTOFMS) in the positive ionization mode was developed for hundreds 
of drugs. The coverage of the method appeared more extensive than for most 
previous methods, enabling sensitive and cost-effective drug testing in a single 
analytical run from a single urine sample. Due to the utilization of mass 
fragmentation, isotopic pattern, and metabolite pattern, the method produced 
testing results with an identification reliability comparable to dedicated target 
analysis. In addition, due to the nontargeted acquisition of full mass range 
broadband data, retrospective data mining and tentative identification of 
compounds without a reference standard was possible.  
Using the developed method, approximately one hundred drugs were identified 
on a routine basis including multiple NPS. Automated data processing allowed for 
the straightforward interpretation of results without requiring an experienced 
9 
analyst. The method outperformed immunoassay drug testing as well as a 
pretargeted QTOFMS approach performed on the same platform in terms of 
specificity, sensitivity, and scope. The limit of identification (LOI) in urine remained 
at a low ng/mL level for the majority of drugs. For example, LOI for buprenorphine 
and methamphetamine reached 1 ng/mL and 6.5 ng/mL, respectively. Cannabis, on 
the other hand, exhibited a higher but acceptable LOI at 15 ng/mL in the positive 
mode. For some NPS, subnanogram limits were reached.  
The study of drug abuse patterns revealed a high prevalence of multiple drug 
abuse among all study subjects regardless of their treatment status. In particular, it 
was common among those subjects not routinely attending medical treatment for 
their drug problem. The most common set of abused substances consisted of 
buprenorphine, benzodiazepines, amphetamine, and cannabis, although subjects 
receiving opioid maintenance treatment more rarely abused buprenorphine. Other 
drugs of abuse always accompanied NPS findings, and NPS were most commonly 
identified in samples from individuals not receiving treatment. The analytically 
confirmed drug profiles of problematic Finnish drug users are reported here for the 
first time with a substantial accuracy, and the findings suggest that treatment for 
drug dependence helps reduce drug abuse. It is anticipated that the urine drug 
testing method presented in this thesis will find additional applications in future 





Drug testing plays a vital role in forensic and clinical toxicology. Forensic toxicology 
answers questions with judicial implications involving cause of death investigations, 
driving under the influence of drugs, drug-facilitated crimes, and workplace drug 
testing. The most important areas of clinical toxicology related to drug testing 
consist of emergency toxicology and the treatment of drug abusers. The current 
trend in drug testing employs analytical techniques based on mass spectrometry 
(MS). In particular, high-resolution mass spectrometry (HRMS) provides 
advantages in terms of its sensitivity, selectivity, and flexibility, and consequently is 
becoming the most appealing approach to drug testing [1]. 
In Finland, multiple substance abuse is frequent and often involves 
intravenously administered buprenorphine or amphetamine [2,3]. Annually, more 
than 6,000 samples from apprehended drivers reveal illicit or medicinal drugs and 
approximately 500 fatal poisonings result from drugs. Recently, new psychoactive 
substances (NPS) appeared on the recreational drugs market. These drugs have 
effects resembling those of conventional drugs, while exhibiting higher potencies 
than their controlled counterparts. However, little is known about their metabolism 
and toxicokinetics. In response to scheduling efforts, new variants continuously 
emerge. Due to the transient nature of NPS, they frequently escape both typical drug 
screening methods and legal restrictions. During the last five years, each week two 
new drug variants have been launched on the European drugs market [4]. At 
present, over 620 NPS are being monitored across the European Union [5]. 
The NPS phenomenon poses challenges not only for drug testing laboratories 
but also for health-care services, as well as drug users themselves. Conventional 
drug testing methods rely on predetermined reference data obtained from 
commercially available reference standards. Due to the expanding repertoire of 
NPS, new reference standards slowly become available, thus complicating the 
development of NPS identification methods. Within emergency toxicology, 
clinicians face difficulties related to the scarcity of data on treatment strategies for 
NPS intoxications. In addition, NPS users are often unaware of the exact drug they 
are consuming, thereby increasing the risk of dosing errors and subsequent 
overdoses. The abuse of drugs, including NPS, will obviously become more 
prevalent [6], giving rise to an increased demand for drug-related health-care 
services.  
An ideal drug screening method would cover all abused substances, whether 
known or unknown at the time of analysis. It is hypothesized that among available 
techniques HRMS is best suited for the detection of hundreds of drugs and 
metabolites at ng/mL concentrations in biological samples. In addition to its 
sensitivity and selectivity, other advantages of HRMS include nontargeted data 
acquisition, retrospective data mining of substances unanticipated at the time of 
analysis, and an easily extendable scope for new analytes. Such features are 
Introduction 
11 
particularly attractive in the detection of NPS displaying back and forth movements 
across drugs markets.  
The ultimate goal of any drug screening method is to enable coverage of the 
entire repertoire of abused drugs, encompassing conventional drugs of abuse, 
prescription drugs, and transient NPS. Moreover, rarely occurring analytes such as 
psilocin should not be neglected [7]. However, the development of a multidrug 
screening method is not straightforward. Sample preparation should be suitable for 
a wide range of lipophilicities and molecular masses. In addition, chromatographic 
separation should cover early-eluting polar compounds while keeping retention 
times (RT) moderate for non-polar drugs as well. HRMS data should be acquired 
without analyte preselection, yet offer a high identification power. If all of these 
requirements are met, comprehensive drug testing should provide reliable patient-
related and epidemiological data at a level that limited drug testing or various 
surveys cannot currently reach. In particular, analytically confirmed drug profiles 
are important in the treatment of drug users. When accurate patterns of drug abuse 
are revealed, treating clinicians can better instruct the drug users and prevent 
hazardous multiple substance abuse, potentially leading to somatic and psychiatric 
emergencies or even fatalities.  
Consequently, today’s drug testing requires a broad-spectrum method at a scope 
beyond conventional targeted analyses. This thesis describes a confirmation-level 
method based on HRMS, using ultra-high performance liquid chromatography-
high-resolution quadrupole time-of-flight mass spectrometry (UHPLC-HR-
QTOFMS). The developed method is one of the first multi-analyte drug screening 
methods that in addition to conventional drugs of abuse covers a variety of NPS, 
including the urinary metabolites of synthetic cannabinoids. The broad-spectrum 
method is applied to gathering information about the epidemiology and reasons for 
drug abuse through the testing of urine samples from various groups of patients.  
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2 REVIEW OF THE LITERATURE
2.1 Drug abuse
Substances that cause addiction induce pleasant states or relieve distress. Their 
continued use induces adaptive changes to the central nervous system resulting in 
physical or psychological dependence [8]. According to the 10th edition of the 
International Classification of Diseases, a diagnosis of substance dependence 
includes at least three of the following: a strong desire to use the substance, 
difficulties in controlling substance taking-behavior, symptoms of withdrawal or 
tolerance, a reduction in alternative pleasures or interests due to substance use, and 
continued substance use despite evidence of harmful consequences [9]. 
Moreover, multiple substance abuse can result in an increased reinforcement 
effect [10]. Some individuals may also use multiple drugs to help alleviate undesired 
side effects, such as the use of sedatives to overcome the insomnia caused by 
stimulants. The route of drug administration also impacts drug use. Injected, 
smoked, and inhaled drugs act more rapidly compared to orally administered drugs, 
thereby exhibiting a higher reinforcement and addiction potential [10]. 
Drugs can act through metabotropic and ionotropic mechanisms. Most drugs of 
abuse act through metabotropic G-protein coupled receptors, which mediate actions 
in seconds. This process influences the level of monoamine neurotransmitters 
noradrenaline, dopamine, and serotonin. Dopamine, however, plays a key role in 
causing euphoria and reinforcing behavior. Other drugs, such as benzodiazepines 
and phencyclidine, act through the ionotropic mechanism involving ligand-gated 
ion channels that mediate synaptic transmission in milliseconds. The gamma-
aminobutyric acid (GABA) and N-methyl-D-aspartate (NMDA) receptors represent 
examples of ionotropic receptors [8]. 
The characterization of antidepressants based on their transporter selectivity is 
an established practice, which can also be used for the characterization of drugs of 
abuse [11]. Stimulants can be classified based on their relative serotonergic and 
dopaminergic activity using the dopamine/serotonin transporter (DAT/SERT) 
inhibition ratio. Such ratios, derived from in vitro studies, help predict the clinical 
toxicity of new drugs and their addiction potential. A low DAT/SERT ratio (below 
0.1) indicates a tenfold greater relative serotonergic versus dopaminergic activity, 
similar to that for 3,4-methylenedioxymethamphetamine (MDMA). A high ratio 
(above 10) corresponds to a greater relative dopaminergic activity similar to that for 
methamphetamine. A high DAT/SERT inhibition ratio indicates strong stimulant 
effects and a higher potential for addiction [12]. Table 1 provides an overview of 
different drug classes focusing on drugs—both scheduled and unscheduled—with 
abuse potential. In addition, the DAT/SERT ratios are presented for stimulants. The 
following sections in this chapter focus on drug abuse involving conventional drugs, 
prescription drugs, and NPS. In particular, NPS are discussed in greater detail. 
Review of the Literature 
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Table 1. Examples of drugs with an abuse potential [12-14].
 Category Effect Target of action 
Cannabinoids    
AB-FUBINACAA synthetic cannabinoid anxiolytic CB1 
JWH-018A,B synthetic cannabinoid anxiolytic CB1 
Δ9-tetrahydrocannabinol (THC)A,B natural cannabis anxiolytic CB1 (partial) 
Hallucinogens    
DiphenidineA phencyclidine analog dissociative NMDA 
Lysergic acid diethylamide (LSD)A,B ergotamine psychedelic DA-SER 
MethoxetamineA,B ketamine analog dissociative NMDA, DA 
PsilocinA,B tryptamine psychedelic SER 
Opioids    
BuprenorphineB medium opioid sedative-analgesic μ (partial), κ antagonist 
CodeineB weak opioid sedative-analgesic μ 
FentanylB strong opioid sedative-analgesic μ 
MethadoneB strong opioid sedative-analgesic μ, NMDA 
Tramadol weak opioid sedative-analgesic μ, SER, noradrenergic 
U-47700A,B designer opioid sedative-analgesic μ 
Sedatives    
EtizolamA,B benzodiazepine sedative-anxiolytic GABA 
FlubromazepamA,B benzodiazepine sedative-anxiolytic GABA 
Hydroxyzine antihistamine sedative-anxiolytic H1  




TemazepamB benzodiazepine sedative-hypnotic GABA 
ZolpidemB imidazopyridine sedative-hypnotic GABA 
Stimulants   DAT/SERTC 
Alpha-pyrrolidinovalerophenone (α-PVP)A,B cathinone stimulant DA 6020 
AmphetamineA,B phenethylamine stimulant DA 40 
CocaineA,B cocaine stimulant DA-SER 3.1 
Desoxypipradrol (2-DPMP)A,B pipradrol stimulant DA 1328 
Ethylone (bk-MDEA)A cathinone empathogen-stimulant DA-SER 0.8 
Methylenedioxymethamphetamine (MDMA)A,B phenethylamine empathogen SER 0.08 
Methylenedioxypyrovalerone (MDPV)A,B cathinone stimulant DA 300 
MethamphetamineA,B phenethylamine stimulant DA 22 
MethylphenidateB phenethylamine stimulant DA 6725 
Para-methoxyamphetamine (PMA)A,B phenethylamine empathogen SER 0.03 
A, Not in normal therapeutic use in Finland; B, Controlled under the narcotics law in Finland; C, A low DAT/SERT 
ratio (<0.1) indicates a tenfold greater serotonergic vs dopaminergic activity; a high DAT/SERT ratio (>10) 
indicates a greater dopaminergic vs serotonergic activity; CB1, cannabinoid receptor agonist; DA, dopaminergic; 
DAT/SERT, dopamine/serotonin transporter inhibition ratio; GABA, gabaergic; H1, histamine receptor antagonist; 
NMDA, N-methyl-D-aspartate receptor antagonist; SER, serotonergic; μ, μ-opioid receptor agonist.  
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2.1.1 Conventional drugs of abuse
In Finland, the most common conventional drugs of abuse consist of amphetamine 
and cannabis, while heroin use is virtually non-existent [2,5,15]. In 2012, the 
number of problem amphetamine users stood at 11,000 to 18,000 [16]. 
Amphetamines inhibit the transporters of all three monoamine neurotransmitters. 
They also inhibit the monoamine oxidase and promote the release of monoamines 
[8]. The enhancement of dopaminergic neurotransmission predominates with 
amphetamine and methamphetamine, while MDMA primarily increases the levels 
of serotonin and noradrenaline [12]. MDMA is the prototypical empathogen or 
entactogen drug producing feelings of emotional empathy while other stimulants 
arouse and stimulate users [12]. Adverse effects associated with stimulants include 
tachycardia, hyperthermia, insomnia, anxiety, depression, and paranoia [17]. 
MDMA abuse is associated with a higher serotonergic toxicity than other stimulants 
involving risks for hyperthermia, seizures, and cardiac arrest [18]. 
Cannabis, specifically Δ9-tetrahydrocannabinol, acts through cannabinoid 
receptors CB1 and CB2. The CB1 receptors are primarily situated in the brain, while 
the CB2 receptors are found in the spleen and the immune system tissues [13]. The 
psychotropic effects of cannabis are mainly caused by the activation of CB1 receptors 
[19]. In addition, cannabis appears to enhance dopaminergic activity. The 
psychotropic effects of cannabis include euphoria, relaxation, and the enhancement 
of sensory perception. Furthermore, cannabis has analgesic, anticonvulsant, and 
cardiovascular effects. Adverse effects consist of panic attacks, tachycardia, and 
depersonalization. Chronic cannabis use at high doses may cause long-term 
impairment of cognitive abilities [19]. 
2.1.2 Abused prescription drugs
Contrary to conventional drugs of abuse, prescription drugs typically regarded as 
medication and endorsed by clinicians give rise to misconceptions whereby they are 
considered as safe substances of abuse [10]. Often abuse doses, excluding opioids, 
are much higher than therapeutic doses. In Finland, the abuse of prescription 
opioids is a major cause for concern. Estimates for the number of problematic 
Finnish opioid users in 2012 reached 13,000 to 15,000 [16]. The top five drugs 
causing fatalities in 2013 consisted of four opioids: buprenorphine, tramadol, 
codeine, and oxycodone [2]. Opioids induce sedative and analgesic effects by 
responding to opioid receptors μ, κ, and δ, and the opioid receptor-like 1 (ORL1). 
The μ-receptor is primarily responsible for the analgesic effects of opioids. Strong 
opioids are used to combat severe pain and in opioid maintenance treatment, while 
weak opioids typically target mild and moderate pain. Respiratory depression and 
oversedation represent the most severe adverse effects of opioids. Concomitant use 
of other central nervous system depressants such as alcohol or benzodiazepines 
increase the risk of fatal poisoning [20,21]. 
Pregabalin was the third most common drug causing fatal poisonings in 2013 
[2]. Typically, it is used to treat neuropathic pain, epilepsy, and generalized anxiety 
disorder. Gabapentin, like pregabalin, increases the synthesis of GABA in the brain, 
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reducing the release of excitatory neurotransmitters. Both of these gabapentinoids—
particularly pregabalin—appear to carry an abuse potential [22]. Pregabalin abuse 
often accompanies multiple substance abuse [22,23] involving higher doses than 
those used for therapeutic purposes [23]. The adverse effects of pregabalin include 
dizziness, loss of consciousness, and visual disturbances. 
Benzodiazepines are prescribed for anxiety, insomnia, and agitation. In Finland, 
these widely abused drugs often accompany concomitant prescription opioid abuse 
[2,20,21]. Benzodiazepines increase the synthesis of the inhibitory neurotransmitter 
GABA by binding to the GABA-benzodiazepine receptor complex located in the 
central nervous system. The adverse effects of benzodiazepines include dizziness, 
lethargy, and rebounding when finishing the use. Chronic use may cause tolerance 
and dependence. 
2.1.3 New psychoactive substances (NPS)
In recent years, NPS have gained worldwide popularity as easily accessible and legal, 
until scheduled, derivatives of classically abused drugs. These novel drugs are often 
sold through internet sites with intriguing brand names under the guises of herbal 
incense, research chemicals, bath salts, food supplements, and plant food, and 
typically carrying the label ‘‘not for human consumption’’ [24-26]. NPS may gain 
their appeal as drugs of abuse due to the misconception that they are safe 
alternatives to classic illicit drugs. Furthermore, curiosity arises from their low 
prices and attractive packaging. NPS are compounds not controlled by the 1961 
Single Convention on Narcotic Drugs or the 1971 Convention on Psychotropic 
Substances, despite potentially posing public health risks. In addition to new 
molecular compositions, the term ‘‘new’’ comprises substances recently made 
available on the recreational drugs market regardless of prior concerns regarding 
their toxicity [25]. Many NPS initially underwent investigation as medicinal drugs, 
but were rejected due to their harmful side effects or ineffectiveness. Despite 
preventive actions to schedule NPS as controlled substances, new derivatives with 
slightly altered structures emerge on the recreational drugs market. Such dynamic 
changes appear in the number of NPS annually reported by the European 
Monitoring Centre for Drugs and Drug Addiction and by the United Nations Office 
on Drugs and Crime. A record 101 NPS were reported through the European Union 
early warning system in 2014. After having increased for six years, a decrease in the 
number of NPS was found in 2015, and during 2016, 66 NPS were reported in 
Europe [5]. The largest classes of emerging NPS in 2016 consisted of synthetic 
cathinones, synthetic cannabinoid receptor agonists (synthetic cannabinoids), 
opioids, and substances not fitting in other monitored groups. Figure 1 illustrates 
the diversity in the chemical structures for select NPS. 
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Figure 1. Structures of new psychoactive substances including (A) synthetic cannabinoids, (B) 
synthetic cathinones, (C) phenethylamines, (D) opioids, and (E) sedatives. Alpha-PVP, alpha-
pyrrolidinovalerophenone; MDPV, methylenedioxypyrovalerone; PMMA, para-
methoxymethamphetamine.
 
The desired effects of NPS often resemble those of their controlled counterparts 
producing feelings of relaxation, euphoria, dissociation, weightlessness, sedation, 
and anxiolysis [27]. Synthetic cathinones exhibit clinical similarities to 
amphetamines [26]; correspondingly, these β-ketoamphetamines act as central 
nervous system stimulants affecting the levels of monoamine neurotransmitters 
[28,29]. All synthetic cathinones, however, exhibit a higher dopaminergic activity 
than their non-β-ketoamphetamine analogs suggesting a stronger stimulant effect 
and a greater risk for dependence [12]. The sympathomimetic effects of both 
phenethylamines and piperazines are, like those of cathinones, caused by 
monoamine neurotransmitters [30,31]. The adverse effects of the sympathomimetic 
drugs include agitation, tachycardia, hypertension, and hyperthermia. The 
toxidrome in overdoses consists of renal and respiratory failure, psychosis, life-
threatening cardiovascular effects, and death [12,13,26,27,30,32]. 
Similar to natural cannabis, its synthetic derivatives tend towards the 
cannabinoid receptors CB1 and CB2 [33], but pose a higher risk of overdose [34] due 
to their more potent receptor agonism. The toxidrome of synthetic cannabinoids is 
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similar to that of a high dose of natural cannabis, but with more serious adverse 
effects including extreme agitation, hallucination, hypertension, cognitive 
impairment, and seizures [27,34-37]. 
Depressant-type NPS consist of opioids and benzodiazepines that interact with 
the opioid and GABA receptors, respectively. Both drug classes carry adverse effects 
resembling those of medicinal opioids and benzodiazepines, although they pose a 
higher risk for accidental overdose [27]. Data on NPS toxicity—particularly the long-
term risks associated with the abuse of these novel drugs—remain scarce. Moreover, 
with NPS the dose causing the desired effect, impairment and toxicity are fickle 
given their unpredictable dose-response relationship and often a higher potency 
than conventional drugs [38]. 
Given the limited knowledge on the toxicokinetics of emerging NPS, the 
metabolism of NPS must be studied before establishing a urine drug screening 
procedure. In particular, researchers must solve whether the parent compounds or 
metabolites should serve as the main target analytes [39]. The primary phase I 
biotransformations for NPS include dealkylation, methylation, and hydroxylation, 
which are catalyzed by cytochrome P450 enzymes. Phase II reactions typically 
involve conjugation to glucuronic acid via UDP-glucuronosyltransferase enzymes 
[13]. Contrary to other NPS, synthetic cannabinoids undergo extensive oxidative 
metabolism, whereby only metabolites are found in the urine [40,41] with a few 
exceptional cases [42]. Because of the high lipophilicity of synthetic cannabinoids, 
adipose tissue may serve as an alternative specimen in fatalities given the increased 
cannabinoid concentrations [43-45]. 
NPS have caused numerous fatalities [4,15,24,46]. Unlike natural cannabis, 
deaths either directly or indirectly resulting from synthetic cannabinoids do exist 
[43-45,47-60]. These reports clearly indicate that synthetic cannabinoids should not 
be viewed as a safe alternative to marijuana, which poses only a limited acute 
toxicity. Furthermore, outbreaks of mass poisonings associated with the newer 
variants of synthetic cannabinoids have been reported [61-65]. The high potency of 
recent variants, the unknown dose-response ratio, and the poor manufacturing 
procedures resulting in inconsistent substance compositions in herbal products 
attribute to such deaths [66]. Moreover, the new practice of selling pure powders of 
novel cannabinoids may increase the risk of overdose [37]. 
Current data on treatment strategies for acute NPS intoxication remain limited. 
Several factors exacerbate the development of such guidelines limiting their 
usefulness. These include the high frequency of multiple substance abuse, the 
impurity of NPS products, individual differences in tolerance, and, primarily, the 
uncertainty of the particular NPS used [67]. In addition to supportive care, 
antipsychotics and benzodiazepines have been used to manage symptoms, anxiety, 
and agitation in intoxication caused by synthetic cannabinoids [36,67-70]. 
Treatment protocols for stimulant toxicity caused by an NPS or for an established 
recreational drug do not differ greatly. A serotonin antagonist cyproheptadine can 
directly decrease any effects caused by high serotonin concentrations. In addition, 
hyperthermia should be treated using cooling measures [70,71]. Sympathomimetic 
symptoms and agitation associated with piperazine toxicity are managed similar to 
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stimulants [70], although antipsychotics should be avoided due to the increased 
probability of extrapyramidal side effects, hypertension, arrhythmias, and 
thermoregulation interference [72]. Naloxone should always be administered to 
counter the adverse effects caused by novel opioids [73-75]. 
While health professionals are likely to come into contact with NPS, most have 
insufficient knowledge of such substances. Currently, diagnosing NPS use remains 
difficult within clinical toxicology since the majority of NPS escape routine detection 
[76]. In general, only specialized drug testing laboratories possess the appropriate 
instrumentation for NPS detection. A method allowing for the detection of NPS 
should feature a generic sample preparation and chromatography, and laboratory 
analysis should cover a wide variety of drugs, both conventional and novel, at the 
relevant concentration levels. As yet, previously existing methods do not fully meet 
all of these requirements. 
2.2 Drugs of abuse testing
Toxicological drug screening analyses have traditionally relied upon a two-step 
procedure comprising immunoanalysis and subsequent confirmation of a 
presumptive positive result using gas chromatography-mass spectrometry (GC-MS). 
The benefits of atmospheric pressure ionization techniques, such as electrospray 
ionization (ESI) which often allows the detection of an intact protonated molecule, 
have shifted the focus to liquid chromatography-mass spectrometry (LC-MS), in 
particular, LC coupled with tandem mass spectrometry (MS/MS) [7,77-79]. 
Furthermore, LC-MS allows for the detection of NPS, specifically their polar and 
less volatile urinary metabolites without requiring laborious derivatization [77,78] 
while overcoming issues of thermal degradation during GC-MS [80]. In general, 
data acquisition through MS techniques can fall into targeted and nontargeted 
approaches. Targeted data acquisition relies on analyte preselection, while 
nontargeted acquisition enables the collection of data without preset criteria. In 
particular, the powerful combination of UHPLC and HRMS emerges as an attractive 
choice for drug screening. 
2.2.1 Immunoassays
Immunoassay techniques for drug testing offer simplicity, rapidity, and a high-
throughput capacity with minimal sample preparation. Such techniques provide a 
cost-effective means to detect the presence of a particular drug class, exhibiting an 
apparent sum concentration above a specific cut-off level. All positive immunoassay 
results, however, require confirmation using an MS technique if the results are 
intended to serve a judicial purpose or if sanctions affecting the patient-doctor 
relationship are likely to follow. The majority of immunoassays only cover classically 
abused drugs, and consequently, many NPS escape detection [76]. The lack of 
antibodies hinders the applicability of immunoassays for the detection of NPS. A 
typical immunoassay drug panel in Finland includes amphetamines, 
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benzodiazepines, buprenorphine, cannabis, cocaine, methadone, and opiates. Some 
analytical cross-reactivity using antibodies from established immunochemical 
screening methods has been reported for a few NPS due to their structural 
similarities to conventional drugs [76,81-84]. Such cross-reactivity can be regarded 
as desirable or unwanted depending upon the scope of testing. Regardless, these 
results appear as false positives (FP) if the confirmation analysis cannot identity the 
substance causing the positive immunoassay result.  
Published immunoassay methods for the urinary metabolites of synthetic 
cannabinoids relied on enzyme-linked immunosorbent assays (ELISA) [85-88], 
homogenous enzyme immunoassays (HEIA) [89,90], and biochip array technology-
based immunoassay [91]. An acceptable sensitivity and specificity with a cut-off 
concentration of 5 ng/mL was reached by all assays excluding the biochip array 
technology-based assay. A higher cut-off resulted in poor accuracy due to the curve 
of the HEIA response [90], whereas the performance of the biochip array 
technology improved when the cut-off was increased. The assays targeted the 
metabolites of JWH-018 [85-87,89,91], JWH-250 [85,91], UR-144 [88], or three 
different synthetic cannabinoids [90]. The performance of the assays was acceptable 
with a sensitivity ranging between 80% and 100% and a specificity falling between 
82% and 100%. Cross-reactivity was observed towards a few additional cannabinoid 
variants, while the immunoassay targeting the metabolite of UR-144 showed no 
cross-reactivity towards other synthetic cannabinoids [88]. 
Published studies on immunoassays specific for NPS other than synthetic 
cannabinoids remain limited with several kits for a variety of NPS now commercially 
available [92]. A method based on ELISA that specifically targets the synthetic 
cathinones mephedrone and methylenedioxypyrovalerone (MDPV) exhibited 
experimentally determined cut-off concentrations of 1.25 and 10 ng/mL, 
respectively. Such low levels indicated that these kits may be suitable for serum 
samples below overdose concentrations [76]. A better performance was observed for 
urine samples above the cut-off level proposed by the manufacturer. That is, the 
increased thresholds for mephedrone and MDPV stood at 7.5 and 40 ng/mL, 
respectively. This biochip array technology-based immunoassay yielded an 
extremely high rate of FP leading to a specificity of only 69%, although its sensitivity 
reached 100%. The instability of the analytes attributed to its weak performance, 
since samples were stored from two to four weeks at ambient temperature [93]. 
Another immunochemical application using the biochip array technology showed 
similar results for designer piperazines based on optimized cut-off levels improving 
the specificity (91%) with an acceptable sensitivity (94%). Once again, a prolonged 
sample storage time may have compromised the positivity rate [94]. The biochip 
technique, however, offered a high-throughput screening for thousands of samples 
with a short turnaround time [91,93,94]. 
A major drawback with immunoassays lies in the lack of cross-reactivity of many 
NPS variants using current antibodies. The continuous variability of the drug scene 
renders keeping methods abreast of the latest derivatives difficult. Those 
immunoassays developed specifically for NPS often become outdated once 
commercially available. NPS screening using immunochemical methods includes 
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the production, development, and validation steps, often preceded by metabolism 
studies and the commercial production of new antibodies [87,89,91,93,94]. Such a 
lengthy procedure makes immunoassays generally less useful for NPS screening, 
which prefers a method with a greater flexibility, such as HRMS displaying a high 
sensitivity and specificity [76,90,94]. 
2.2.2 Pretargeted methods based on LC-MS/MS
LC-MS/MS employing a triple quadrupole or hybrid triple quadrupole linear ion 
trap MS/MS allows a higher identification power and sensitivity than that obtained 
by immunoassay. In general, these low-resolution MS (LRMS) approaches require 
analyte preselection. Not many LRMS-based methods appear in the literature for 
the simultaneous detection of NPS and conventional drugs [95-97]. A more common 
approach using LRMS is the development of a method specific to a certain NPS class 
[42,98-103] or multiple NPS classes [104-110]. However, urine testing methods 
using an analyte coverage of more than 50 drugs including different classes of NPS 
remain scarce [95,97,105,111], and all but one [111] were published after the present 
study (I) was completed. The data acquisition mode for most LRMS methods relied 
on selected reaction monitoring, excluding a few library search approaches in which 
the scan mode allowed for the acquisition of product ion spectra [42,97,98,111]. 
Data were acquired in the positive ionization mode. In two LRMS methods, a 
separate run was performed for a few analytes in the negative ionization mode 
[95,103]. Methods for a biological specimen other than urine typically only target 
the parent compounds, while NPS urinalysis [42,99] should always include at least 
the primary metabolites. Urine drug screening targeting only parent drugs could, 
however, be sufficient for stimulant NPS [104,105] although not for synthetic 
cannabinoids [97].  
One disadvantage of NPS screening using LRMS lies in the necessity of knowing 
the target analyte in advance in order to optimize mass fragmentation. The constant 
upsurge of novel NPS variants necessitates incorporating them into existing 
methods [7,112], which is not straightforward using LRMS and requires at least a 
partial revalidation [42,103,105]. Furthermore, reference standards are needed 
during method development delaying particularly the detection of NPS metabolites. 
2.2.3 Accurate mass measurements
The principle of deducing an empirical formula for a compound using a sufficiently 
accurate measurement of its ion was introduced as early as the 1950s [113]. Mass 
accuracy is the deviation between the measured and the theoretical mass of an ion 
often expressed in parts per million (ppm) [114]. Obviously, the smaller the 
difference, the better the mass accuracy. Typically, accurate mass measurements 
with results between 2 to 5 ppm are achieved through periodic calibration [115]. 
Internal and external calibrations represent strategies for mass correction. Using 
internal calibration, mass correction is performed using the reference mass peaks in 
the same mass spectrum as the analyte, while external calibration is performed 
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using the reference masses from the external mass spectrum acquired using similar 
conditions as the analyte spectrum [116]. In fact, mass accuracy can be defined as 
the ability to calibrate the instrument response against a known entity [115]. 
Acquiring high mass-accuracy data requires high-resolution mass analysis using 
techniques such as time-of-flight (TOF), orbitrap, magnetic sector, and Fourier-
transform ion-cyclotron resonance (FT-ICR) [116]. Mass resolving power expresses 
the capacity of a mass analyzer to separate ions from an adjacent mass-charge ratio 
(m/z) demonstrating a measurement precision over a wide m/z range [116,117]. In 
addition, mass resolution is the measurement of the separation of two adjacent 
mass spectral peaks. As such, it is defined in two ways depending upon the mass 
analyzer employed: a 10% valley definition is used for magnetic sector instruments 
and the full width at half maximum (FWHM) definition for quadrupole, FT-ICR, 
orbitrap, and TOF. A mass resolving power of 30,000 FWHM and a mass accuracy 
below 5 ppm are routinely achieved using orthogonal TOF-MS [117]. Table 2 details 
the terminology involved using HRMS. 
 
Table 2. Key terminology involved in high-resolution mass spectrometry [114,118].
Term Definition 
Accurate mass The experimentally measured mass of an ion with a known charge. 
Exact mass The calculated mass of an ion with a specified isotopic composition. 
Mass accuracy The difference between the measured (accurate mass) and theoretical value (exact 




10% valley definition 
 
FWHM definition 
The measure for separating two adjacent mass spectral peaks, for which the observed 
m/z is divided by the minimum difference Δ(m/z) for two ions that can be separated: 
(m/z)/Δ(m/z). 
The value for two mass spectral peaks of equal height separated by a valley with a 
maximum of 10% of the peak height. 
The value for a single mass peak, for which Δ(m/z) is the full width of the peak at half 
its maximum (FWHM) height. 
Mass resolving power The capability of a mass spectrometer to provide a defined value for mass resolution.  
Monoisotopic mass The exact mass of an ion calculated using the most abundant isotope for each 
element. 
 
In mass analysis using orthogonal TOF-MS, the ions are accelerated into the 
flight tube with an electrostatic field orthogonal to the ion beam axis of the ion 
source [119]. Ion introduction occurs by ESI enabling the transfer of compounds 
from the liquid to the gas phase in an ionized state [120]. Next, ions travel a 
predetermined flight path in a field-free drift space and separate according to their 
m/z associated flight times [119,120]. Analyte ions often encounter a reflecting 
electrostatic mirror in the flight path directing them to the detector. A conversion 
dynode and a channel electron multiplier represent the most common detectors 
[120]. The combination of TOF and a quadrupole (Q) provides a high sensitivity, a 
high mass resolution, and a high mass accuracy for both the precursor and product 
ions. QTOF typically comprises the source inlet, three Q (or a combination of Q and 
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hexapoles), and the reflecting TOF described above. Q0 serves as the ion guide, Q1 
represents the mass filter, and Q2 serves as the collision cell in which ions undergo 
collision-induced dissociation (CID) with neutral gas molecules (typically nitrogen) 
to form fragments, namely product ions [121]. 
HRMS gained interest from various disciplines including proteomics [122], 
environmental analyses [123], and food toxicology involving pesticides [124] as well 
as adulterants and contaminants [125]. Today, HRMS is widely used in forensic and 
clinical toxicology [1,7,78,112], including metabolic studies and both qualitative and 
quantitative drug screening applications [126]. Furthermore, HRMS remains quite 
appealing in the analysis of NPS in different biological specimens and was applied to 
several matrices. Table 3 summarizes HRMS screening methods focusing on 
conventional drugs of abuse and multiple NPS classes. In the table, only blood and 
urine testing methods are listed. Several impressive reports documented HRMS 
methods in the analysis of a specific NPS class [90,127-130] as well as for NPS 
detection in hair [131-133]. But, these topics lie beyond the scope of this study. The 
applications listed in Table 3 were primarily performed using QTOFMS, excluding 
one relying on a single-stage TOF-MS [134] and a few applying the orbitrap 
technique [135-139]. Across all methods, LC was used with one exception relying on 
the GC method [140]. A few methods using the negative ionization mode were 
performed in a separate run [141-145] or in parallel to positive ionization by polarity 
switching [135,136]. Three methods applied a nontargeted screening approach with 
no upper limit for analyte coverage [141,142,146]. Analyte coverage ranged from 5 to 
40 in those methods focusing on multiple NPS classes, whereas the range for the 
broader methods reached coverage typically above hundreds of substances. 
However, prior to the drug screening method described in this thesis (I), no 
similarly comprehensive method for urine testing appeared in the literature, while 
only two methods were published for blood samples [143,147]. Subsequent to the 
publication of study (I), other HRMS drug testing methods covering both 
conventional and novel drugs were developed for urine samples [136,142,148].  
In most studies, data acquisition involved no preset criteria for the precursor 
selection. Such data-independent acquisition (DIA) enables the collection of full 
mass range data above a predetermined intensity threshold. All mass data on both 
precursor and product ions were collected by alternating the acquisition between 
low and high collision energies (CE) across a specified mass range. The majority of 
methods captured fragment data applying a CE ramp, while a single [149] or double 
[142] CE was also applied. The DIA approach produced nonselective broadband 
data on mass fragmentation. In three of the DIA approaches, only precursor data 
were acquired [134,143,145], although two gained access to QTOFMS. Another 
approach relies on the selection of the precursor in advance of mass fragmentation 
using data-dependent acquisition (DDA). In DDA, precursor selection was most 
often based on inclusion lists; yet, one study featured the intensity threshold as the 
selection criteria [137]. This type of targeted MS/MS approach produces more 
selective fragmentation data than DIA. Only a few studies have combined 
approaches involving an inclusion list for the production of selective fragment data 
and a parallel full-scan MS acquisition. Such a procedure enables data acquisition 
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for unanticipated precursor ions with [135,148] or without [138,139] fragmentation 
information. Recently, another approach for QTOFMS data acquisition—named the 
sequential windowed acquisition of all theoretical mass spectra (SWATH)—was 
introduced [150]. Similar to DIA, SWATH is also independent of analyte 
preselection, but acquires mass spectra in smaller m/z windows. Figure 2 illustrates 
the three approaches to HRMS data acquisition. 
 
Table 3. LC-QTOFMS-based methods for the analysis of conventional drugs and new 
psychoactive substances (NPS).
Targets Coverage (n) PolarityA Matrix Data acquisition 
NPS and conventional drugs     
Mollerup et al. 2016 [146] nontargeted + B DIA 
Lung et al. 2016 [141] nontargeted +, - B DIA 
Kinyua et al. 2015 [142] nontargeted +, - U,S DIA 
Helfer et al. 2017 [135]B 700 +/- P DDA + parallel FS (DDA) 
Roche et al. 2016 [136]B 616 +/- B,S,U DIA 
Telving et al. 2016 [149] 467 + B DIA 
Roman et al. 2013 [143] 240 +, - B DIA 
Study (I), 2013 >298 (IV) + U DIA 
Pedersen et al. 2013 [147] 256 + B DIA 
Bidny et al. 2017 [144] >185 +, - B DIA 
Teng et al. 2015 [151] 151 + B DIA 
Guale et al. 2013 [134]C >100 + B,S,U DIA 
Li et al. 2013 [137]B 65 + U DDA 
Tsai et al. 2013 [145] 62 +, - U DIA, subsequent DDA 
confirmation 
Paul et al. 2014 [148] 62 + U DDA + parallel FS (DDA) 
Chindarkar et al. 2014 [152] 61 + U DIA 
Multiple NPS classes     
Concheiro et al. 2015 [139]B 40 + U DDA + parallel FS (prec) 
Pasin et al. 2015 [153] 37 + B DIA 
Montesano et al. 2016 [138]B 25 + P DDA + parallel FS (prec) 
Ojanperä et al. 2016 [140]D 5 + B DDA 
A, positive (+) and negative (-) ionization in separate runs (+, -) or by polarity switching (+/-); B, orbitrap; C, single-
stage TOF-MS; D, GC; B, blood; DDA, data-dependent acquisition; DIA, data-independent acquisition; FS, full scan; 
P, plasma; prec, precursor mass data; S, serum; U, urine. 
 
Compound identification was most often based on determining the molecular 
formula from full-scan data by searching the measured HRMS data against in-house 
databases of exact monoisotopic masses. A candidate list generated using empirical 
rules for masses can contain multiple potential formulae, which are further reduced 
by post-acquisition software algorithms [117]. In addition to RT and precursor ion 
mass accuracy matching, substance identification often employs product ion mass 
accuracy and isotopic pattern matches. In addition, the substance identification 
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power is compromised without using product ions [134,143]. Applying mass 
accuracy criteria to product ions also reduces FP [148,152,154]. In addition, using 
predicted data on mass fragmentation [155] and metabolism [156] facilitates the 
tentative identification of NPS and their metabolites [142,146,148]. Relying on 
QTOFMS to avoid FN screening results due to detector saturation can be achieved 
by adding the main isotopes for compounds that occasionally exist at a high 
concentration into the target database [149]. 
Another option for compound identification from accurate mass measurement 
focuses on comparing the measured HR product ion mass spectra to a reference 
mass spectra [157,158]. Among the methods presented in Table 3, three methods 
that apply the orbitrap technique [135,138,139] and one using QTOFMS [142] rely 
on spectrum matching. DDA typically precedes the library search by applying 
inclusion lists to the masses of interest in order to acquire the selective HR product 
ion spectra suitable for spectral comparison. In addition to the minimum scores for 




Figure 2. Data-acquisition approaches for high-resolution mass spectrometry: (A) data-
independent acquisition (DIA) using the wide quadrupole (Q1) passing mode for precursor ions, 
(B) data-dependent acquisition (DDA) using a narrow Q1 window, and (C) sequential windowed 
acquisition of all theoretical mass spectra (SWATH) using the medium Q1 passing mode. 
Modified from reference [159].
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2.3 Epidemiology
Blood-borne infections, overdose morbidity, and mortality constitute some of the 
most adverse consequences of recreational drug abuse. A large-scale longitudinal 
study in Finland summarized the characteristics of drug users seeking treatment for 
substance abuse [3,160,161]. Typically, abuse began with alcohol; during 
adolescence, the introduction of illicit drugs further evolved to an established drug 
habit involving intravenous drug use. Among the study population, the primary 
drugs abused consisted of intravenous opioids, following cannabis and stimulants 
with a high frequency of multiple substance abuse [3]. Compared to the general 
population, treatment-seeking drug users had a more than fivefold risk of 
hospitalization for mental health disorders as the primary diagnosis [160] and a 
nearly ninefold risk of premature death [161]. Blood-borne infections such as HIV 
and hepatitis C were more frequent among stimulant users, while those abusing 
prescription drugs more often received diagnoses of depression and psychosis [160]. 
The most common causes of death included accidental overdose and suicide [161].  
According to the European Monitoring Centre for Drugs and Drug Addiction, the 
prevalence of cannabis use in Finland currently mimics the European average, 
whereas the prevalence of amphetamines lies among the highest levels in Europe 
[5,15]. During 2016, the abuse of methamphetamine, which has historically been 
restricted to the Czech Republic and Slovakia, significantly increased in eastern 
Germany and in Finland [5]. Many European countries report heroin abuse as the 
most prevalent opioid used, while in Finland buprenorphine stands as the most 
frequently abused opioid. A survey on the prevalence of drug use conducted in 2014 
indicated that NPS remain rare in Finland [162]. For instance, the survey revealed 
that the prevalence of synthetic cathinones and synthetic cannabinoids stood below 
1%. Cannabis was the most prevalent drug used (19%) following sedative 
prescription drugs (5%) and amphetamines (3%). However, a Finnish expert panel 
study estimated an increase in drug abuse [6]. In particular, they predicted an 
increase in the abuse of prescription drugs and NPS.  
Results from survey-based studies carry several shortcomings. Firstly, people 
who use drugs may under- or overreport the quantity of drugs they use. Secondly, 
some populations more poorly participate in surveys including substance abusers. 
Finally, the drug users are often unaware of the exact drug they are consuming, 
which is particularly relevant for NPS abuse. An alternative to estimating the 
patterns and trends of drug abuse employs analytically confirmed results. In 
Finland, such methodologies used for the evaluation of drug abuse include waste 
water analysis [163-166], post-mortem toxicology [2,20-22,167,168], studies on 
driving under the influence of drugs (DUID) [23,169-172], and results from opioid-
dependent patients undergoing treatment [173,174]. Although all approaches carry 
limitations and may not be comparable to the general population, they do provide 
valuable analytically confirmed information on trends in the Finnish drug use scene. 
As such, waste water analyses carried out in 2012, 2014, and 2015 revealed that 
amphetamines represented the dominant drugs of abuse in Finland [164-166] with a 
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significant increase in the abuse rate over two years [166]. In terms of NPS, only 
MDPV and methylone were identified [164,165]. Occasional traces of methylone 
were found [165], while MDPV was identified in  Helsinki [165] and at an 
exceptionally high rate in the southeastern region of Finland [164,165]. Among 
weekly trends in drug use, the abuse of MDMA and cocaine were more pronounced 
during weekends indicating their use as recreational party drugs. By contrast, 
amphetamine [164-166] and MDPV [164,165] use were associated with problematic 
drug users due to the consistent concentrations found throughout the week. Similar 
to urinalysis, the determination of NPS in waste water requires preceding studies on 
toxicokinetics, as well as analysis of in-sewer stabilities. Moreover, the wide range of 
NPS together with their sporadic availability on the drugs market hampers detection 
of any individual substance in a municipal sewage network [175]. Analysis of the ten 
most frequent NPS in waste water samples collected from eight European cities 
revealed a low occurrence of NPS with only three synthetic cathinones detected at 
low concentrations [176]. Therefore, a pooled urinalysis from stand-alone pissoirs 
(such as those situated in city centers or in close proximity to night clubs) could 
serve as an alternative to assessing NPS abuse although such results are not 
comparable to the general population as waste water-based epidemiology [175].  
Multiple substance abuse is a common phenomenon among chronic drug users. 
A study of fatal poisonings among dependent drug users submitted for medico-legal 
investigation in five Nordic countries in 2012 revealed a high frequency of multiple 
substance abuse (with 4 to 5 concomitant drugs detected per case) across all 
countries [167]. In Finland, amphetamine stood as the most common stimulant 
drug and buprenorphine represented the primary intoxicant in fatal poisonings. 
Among NPS, few substances were detected across all countries, although the largest 
repertoire was found in Sweden and Finland. In Finland, the most common NPS 
were alpha-pyrrolidinovalerophenone (alpha-PVP), MDPV, and para-
methoxymethamphetamine (PMMA); in Sweden, ethylphenidate, 5-(2-
aminopropyl)indole (5-IT), and the synthetic cannabinoid AM-2201 [167] were 
detected most often. Post-mortem toxicology in Finland between 2011 and 2013 
revealed 80 different NPS in 69 cases, the most frequent being alpha-PVP and 
MDPV [2]. A synthetic cannabinoid was found in only one case involving multiple 
substance abuse. In 14 cases, the detected NPS was regarded as the most important 
contributor to death. Overall, the influence of NPS on the cause of death was 
insignificant in most cases. Multiple substance abuse involving heavy alcohol use 
and buprenorphine abuse stood as the most probable cause of death. However, the 
abuse of stimulant NPS was associated with a higher risk of death by accidental or 
intentional injury [2]. The entry of a dangerous synthetic opioid U-47700 emerged 
in 2016, contributing to eight fatalities in Finland [177]. A subsequent national 
warning was broadcasted to raise awareness among drug users of this hazardous 
and potent opioid. 
A comprehensive post-mortem toxicology database generated in Finland 
facilitated several epidemiological studies on abused drugs such as prescription 
opioids [20,21,168] and gabapentinoids [22]. Poisonings by the weak opioids 
tramadol and codeine were often associated with suicidal overdoses, while the 
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strong opioids methadone and buprenorphine more commonly caused accidental 
poisonings [20,21]. Concomitant benzodiazepine and alcohol use often associated 
with buprenorphine, codeine, and tramadol poisonings increasing opioid toxicity. 
Although fentanyl was the least-abused opioid, this potent drug caused the highest 
number of fatal poisonings among known drug users [168]. The typical victim of a 
fatal poisoning via a prescription opioid was a male drug user aged around 30 years 
[20,21]. 
Studies among drivers apprehended for DUID revealed the range of drugs 
encountered in traffic. Abuse profiles for selected NPS and pregabalin were assessed 
among apprehended Finnish drivers [23,169-171]. All studied NPS (MDPV, 
phenazepam, and 2-diphenylmethylpiperidine (2-DPMP)) as well as pregabalin 
were frequently accompanied by the use of other drugs. Amphetamines and 
benzodiazepines represented the most common concurrently used drugs. The 
typical apprehended driver was a multiple substance user and a 30-something man 
from Southern Finland [169-171]. Phenazepam, however, was often encountered 
near the Russian border. In comparison to Finland, in Russia phenazepam is used 
as a prescription drug for anxiety, epilepsy, and alcohol withdrawal syndrome [170]. 
Moreover, two types of phenazepam users exist: those using multiple sedatives and 
those self-medicating for stimulant withdrawal. When MDPV first entered the 
Finnish drugs market, the incidence of MDPV among apprehended drivers was 
particularly high [169]. However, the prevalence of NPS in traffic and in post-
mortem toxicology differs [170,171], possibly resulting from the lower toxicity of 
some NPS [170]. In both toxicological investigations, the prevalence of MDPV 
decreased after it was banned [172]. Such a decline in MDPV use appears promising 
for the public welfare, since MDPV may be associated with a higher risk of suicide 
[2,172]. 
Prevalence studies on other clinical samples in Finland include monitoring 
MDPV use among opioid-dependent patients with incidental amphetamine abuse 
[173]. Among this narrow study population, MDPV was detected among 26%. 
Another Finnish study revealed that an inadequate dose of opioid maintenance 
treatment medication associated with a higher probability of benzodiazepine abuse 
[174]. These studies emphasize the importance of drug testing within opioid 
maintenance treatment. In particular, treatment safety may improve if patients with 
confirmed drug use are denied take-home doses of their substitution therapy [173]. 
Laboratory-based studies among Finnish drug users remain scarce, although 
established drug users likely use multiple substances and NPS [4]. Such use calls for 
new research relying on modern analytical techniques enabling the assessment of 
accurate drug abuse profiles. 
In Sweden, a joint nationwide project STRIDA (an acronym derived from the 
Swedish name of the project) began in 2010 to monitor the incidence of NPS use by 
analyzing drug intoxication cases presenting at emergency departments and in 
intensive care units across the country [178,179]. Project outcomes included a better 
understanding of clinical features related to NPS intoxication and analytically 
verified national trends on drug use. The project produced valuable toxicity and 
prevalence data from NPS intoxication involving novel fentanyl [73,74,180] and 
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opioid [75] analogs, synthetic cathinones [181-183], synthetic cannabinoids [37], 
dissociatives [184,185], and other NPS stimulants [186,187]. However, the 
assessment of a specific toxidrome for a certain NPS was not straightforward due to 
the high incidence of multiple substance use. A unique ototoxic reaction was, 
however, observed for the designer opioid MT-45 [75]. Such bilateral hearing loss is 
typically transient, although one patient showed a permanent defect. Contrary to 
other NPS studied within the STRIDA project, the abuse of alpha-PVP and MDPV 
were thought to be particularly common among established stimulant drug users 
due to their high median age, the high prevalence of hepatitis C, and the high 
frequency of intravenous administration [181,182]. The drug use situation in 
Sweden can to some extent reflect the Finnish context given various similarities in 
drug profiles [167]. As exemplified by the vast number of NPS encountered in the 
Swedish emergency toxicological setting, such nationwide co-operation facilitates 
the exchange of information and raises overall awareness of NPS. 
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3 AIMS OF THE STUDY
This study aimed: 
 
To develop and validate a multidrug screening procedure enabling the 
simultaneous detection of both traditional and new psychoactive 
substances (NPS) by ultra-high performance liquid 
chromatography/high-resolution quadrupole time-of-flight mass 
spectrometry (UHPLC-HR-QTOFMS) (I). 
 
To evaluate the capability of the UHPLC-HR-QTOFMS method as a 
substitute for conventional immunoassays in drug screening (III). 
To compare two general mass spectrometry-based workflows for data 
acquisition and processing (II). 
To utilize data-independent broadband mass spectral data followed by a 
reverse database search for tentative compound identification of NPS 
metabolites (I). 
To demonstrate the applicability of broadband data to identify co-eluting 
isomeric and isobaric compounds (II).  
 
To apply the developed method to the collection of epidemiological data 
and to the assessment of patterns of drug abuse among drug users with 
different treatment statuses (IV and V).  
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4 MATERIALS AND METHODS
4.1 Materials
4.1.1 Chemicals and reagents
The reference standards, which were of pharmaceutical purity, for the majority of 
drugs were purchased from several pharmaceutical companies. Some NPS consisted 
of seized material obtained from the Finnish Customs Agency. Reagents for 
immunoanalysis were provided by Siemens (Erlangen, Germany), Abbott 
Laboratories (Abbott Park, IL, USA), and Medichem (Steinenbronn, Germany) 
(III). All other chemicals were of analytical or LC-MS-grade purity and were 
obtained from various suppliers. 
4.1.2 Urine samples
Clinical urine samples were collected at health-care units and sent to the laboratory 
for drug testing (I, II, IV, and V), while post-mortem urine samples were collected 
by forensic pathologists during medico-legal autopsies (I and III) for routine 
toxicological screening. In addition, the Institute of Forensic Medicine at the 
University of Freiburg (Germany) provided urine samples previously confirmed 
positive for synthetic cannabinoids (I). The analysis of some of the submitted 
samples formed a part of routine clinical treatment for drug users (IV and V). Drug-
free urine samples from healthy volunteers were used for the validation studies (I 
and II). 
Sample selection was performed using different criteria depending on the study 
design. To evaluate the applicability of the UHPLC-HR-QTOFMS drug screening 
method, 50 samples previously found positive for drugs of abuse (I) were analyzed. 
For the performance comparison study, 279 consecutive post-mortem urine samples 
(III) and 50 clinical samples (II), including both drug-positive and drug-negative 
samples, were analyzed using UHPLC-HR-QTOFMS and the results were compared 
to the immunoassay (III) or to DDA data acquisition (II), respectively. The results 
from routine analyses remained blinded until completion of analyses (II and III). 
Samples from drug users in treatment were acquired consecutively between October 
2013 and April 2014 (n = 200, V) and from 36 anonymous volunteers collected 
between December 2013 and March 2014 (n = 67, IV). A total of 32 anonymous 
subjects irregularly visiting a harm reduction unit provided 34 samples (IV). 
All treated study subjects provided their written consent for urine analysis as a 
part of their treatment (IV and V). The study protocols were approved by the 
Medical Director of A-Clinic Foundation (IV) and the Institutional Review Board of 
the Department of Psychiatry, Helsinki University Central Hospital (V). The other 
samples studied used anonymous personal identifiers solely intended for method 
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development and comparison purposes, and, therefore, were performed with 
permission from the Department of Forensic Medicine without requiring separate 
approval from the Ethical Committee (I–III). 
4.2 Sample preparation
All urine samples excluding those subjected to immunoanalysis (III) underwent the 
same sample preparation prior to UHPLC-HR-QTOFMS analysis. Samples were 
hydrolyzed with β-glucuronidase and extracted using solid-phase extraction. The 
mixed-mode sorbent comprised reversed-phase (C4) and cation exchange 
properties. Some modifications were performed during the study: the sample 
amount was decreased from 1 mL (I) to 0.5 mL (II–V), the volume of reconstitution 
solvent was decreased from 150 μL (I) to 75 μL (III, IV, and V), but increased to 
500 μL (II) when increasing the injection volume from 1 μL (I, III, IV, and V) to 5 
μL (II). All modifications were made due to the introduction of an upgraded analog 
to a digital converter resulting in an improved scanning speed, and to widen the 
dynamic range by avoiding column overload and detector saturation caused by 
extremely high drug concentrations. 
4.3 Instrumentation and analytical methods
4.3.1 Immunoassay
Untreated urine samples were analyzed using a Vitalab Viva analyzer applying the 
enzyme multiplied immunoassay technique (EMIT) according to the manufacturer’s 
recommendations for the cut-off concentrations (III, Siemens, Erlangen, Germany). 
Analysis was based on competition between a free drug and an enzyme-labelled 
drug for antibody binding sites. A sample with a drug concentration exceeding the 
cut-off produced a measurable absorbance change directly proportional to the 
urinary drug concentration. 
4.3.2 Ultra-high performance liquid chromatography/high-resolution 
quadrupole time-of-flight mass spectrometry (UHPLC-HR-
QTOFMS)
The UHPLC-HR-QTOFMS system consisted of a maXis Impact (I and III) or an 
Impact HD (II, IV, and V) mass spectrometer (Bruker Daltonics, Bremen, 
Germany) combined with a Dionex Ultimate 3000 series UHPLC (Sunnyvale, CA, 
USA). The UHPLC instrument included a vacuum degasser, a binary pump, a 
temperature-controlled autosampler, and a column oven. Chromatographic 
separation was performed using a Waters HSS T3 (150 mm × 2.1 mm, 1.8 μm) 
column and an equivalent precolumn (2.1 mm ×5.0 mm) in the gradient mode at 
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60°C. The mobile phase consisted of 2-mM ammonium acetate in 0.1% formic acid 
and methanol. The flow rate was 0.3 mL/min. 
The HR-QTOFMS instrument was equipped with an ESI source and a six-port 
divert valve. The mass resolving power specification of the instrument for m/z 1222 
was ≥40,000 FWHM. In practice, the median mass resolving power for alpha-PVP 
(m/z 232.1696) was 24,700 FWHM. The instrument was operated in the positive 
ion mode acquiring data at an m/z range of 50 to 700 using DIA (I–V) and DDA 
(II). Mass fragmentation was performed with broadband collision-induced 
dissociation (bbCID, I–V) or with a preselected CE for targeted compounds (II). 
Both external instrument calibration and post-run internal mass scale calibration of 
individual samples were performed with a sodium formate solution using nine 
cluster ions with exact masses between 90.9766 and 634.8760. Figure 3 presents the 
workflow for urine drug screening employing DIA and DDA. 
The data processing software for the UHPLC-HR-QTOFMS acquisition data 
consisted of DataAnalysis (I: 4.1 (version 358); II–V: 4.2 (version 376)), Target 
Analysis 1.3 (I–V), and LibraryEditor 4.1 (II, Bruker Daltonics). Substance 
identification was based on an automated post-acquisition reverse database search 
with preset reporting criteria (I–V) and a comparison of the measured product ion 
spectra to the reference mass spectra (II). For the database search, drug 
identification criteria were set for the mass accuracy (I: ±3 mDa; II–V: ±2.5 mDa), 
peak area counts for the product (I: 100; II–V: 2,200) and precursor ions (I: 
10,000; II–V: 20,000), and RT (I–V: ±0.2 min). The value for the precursor 
isotopic pattern match served as an additional attribute for identification. In 
addition, individual area criteria were applied for synthetic cannabinoids, internal 
standards, and for a few individual drugs (II–V). Compounds fulfilling the 
predetermined criteria were reported in the list of positive findings. For the library 
search (II), the measured and the reference spectra were compared using scores for 
spectral similarity. 
An in-house database of exact masses (I–V) and a spectrum library of 200 
compounds (II) were created by analyzing the reference standards of drugs, and 
further assigning the molecular formulae for the precursor and product ions and the 
most characteristic product ion spectra (II). Initially, the database of toxicologically 
relevant drugs of abuse comprised 277 compound entries (I). The analyte panel was 
further extended to cover more drugs and emerging NPS together with their known 
or predicted metabolites yielding a collection of approximately 550 compound 
entries (III, IV, and V). For the acquisition mode comparison, a subset of the 
database containing 200 compounds was created to match the scope of the 
spectrum library (II). The ACD/MS Fragmenter (version 11.01, Advanced Chemistry 
Development, Toronto, Canada) and SmartFormula3D (Bruker Daltonics) software 
programs were used to assign molecular formulae for product ions when adding 
new entries to the database. 
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Figure 3. Workflows for post-targeted (I–V) and pretargeted (II) urine drug screening approaches 
using UHPLC-HR-QTOFMS.
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5 RESULTS AND DISCUSSION
5.1 Drug screening based on data-independent 
acquisition (DIA)
A urine screening method based on UHPLC coupled with HR-QTOFMS was 
developed for drugs of abuse featuring a scope beyond ordinary drug testing. Using 
broadband DIA, both conventional drugs and NPS, including the urinary 
metabolites of synthetic cannabinoids, were encompassed for the first time. In 
previous methods, no more than nine metabolites for synthetic cannabinoids were 
included [42,99,127]. More recently, two HRMS-based screening methods relying 
on DIA were developed exclusively for the urinary metabolites of synthetic 
cannabinoids [90,129]. Moreover, an HRMS screening method covering hundreds 
of drugs including synthetic cannabinoids was developed for blood samples [149] as 
well as a single-stage TOF-MS screening method involving only the parent synthetic 
cannabinoids for blood, serum, and urine samples [134]. However, the 
comprehensive screening method developed in this thesis (I) remains quite unique 
in its ability to cover both the urinary metabolites of synthetic cannabinoids and 
other drugs of abuse including amphetamines, cathinones, cocaine, hallucinogens, 
natural cannabis, opioids, and sedatives. One reason this challenge persists is the 
implementation of lipophilic synthetic cannabinoids and hydrophilic stimulant NPS 
into the same method, while maintaining a satisfactory analysis time. A different 
solution lies in applying two separate chromatographic runs with a higher 
proportion of organic content in the mobile phase for synthetic cannabinoids, as 
illustrated through the use of an LC-MS/MS-based screening method for hair 
samples [108]. 
Initially, the in-house database included 277 compound entries involving exact 
masses for the precursor ions and for the majority of product ions, in addition to RT 
when a reference standard was available (I). The database was continually updated 
with emerging NPS (III, IV, and V) to contain approximately 550 compound 
entries of toxicological relevance. Incorporating rarely occurring substances, such as 
psilocin and lysergic acid diethylamine (LSD), into the screening method fulfils the 
requirement for systematic toxicological analysis [7]. Substance identification was 
completed through post-acquisition reverse database search using the acceptance 
criteria for mass accuracy, area counts for both product and precursor ions, and RT. 
The precursor isotopic pattern supported the identification. 
 
Results and Discussion 
35 
Table 4. Limit of identification (LOI), mass accuracy, and mass resolving power for selected 
compounds (I).
  Mass accuracy 
(mDa) 
Mass resolving power 
(FWHM) 
Compound LOI (ng/mL) A B A B 
Cannabinoids      
AM-2201 0.4 0.6 0.4 30,577 30,158 
HU-210 10 0.1 0.4 24,120 17,333 
JWH-018-5-pentanoic acid 2.0 0.1 0.2 25,957 23,689 
THC-COOH 15 0.2 0.3 19,764 18,212 
Cathinones      
MDPV 0.8 0.2 0.2 27,936 25,417 
Methylone 1.5 0.1 0.1 20,445 18,759 
Opioids      
Buprenorphine 1.0 1.3 1.1 27,116 25,417 
Morphine 2.0 0.2 0.1 19,783 18,016 
Amphetamines      
MDMA 0.9 NA NA NA NA 
Methamphetamine 6.5 0.4 0.5 16,959 16,324 
A studied in a neat standard, LOI and B in urine samples spiked before extraction. FWHM, full width at half 
maximum; MDMA, methylenedioxymethamphetamine; MDPV, methylenedioxypyrovalerone; NA, not assigned; 
THC-COOH, 11-nor-9-carboxy-Δ9-tetrahydrocannabinol. 
 
The sensitivity of the method was adequate for the screening of conventional 
drugs and NPS as shown in Table 4, which provides LOI for selected drugs of abuse. 
LOI was defined as the concentration at which the compound was identified using 
the preset acceptance criteria. In practice, this meant a precursor area roughly 
twofold the minimum acceptance criterion. The median LOI for the representative 
set of 75 drugs of abuse reached 1 ng/mL. Cannabinoids lacking nitrogen possessed 
the highest LOI, which were poorly ionized in the positive mode making their 
incorporation into multi-analyte methods challenging [42]. For such compounds, a 
separate analysis in the negative ionization mode could allow for a better ionization 
efficiency [95,145]. Another option might rely on employing an instrument capable 
of rapid polarity switching to achieve a better LOI [135]. 
For a majority of the 20 model compounds, the matrix effect, recovery of 
extraction, and overall process efficiency were adequate within the observed ranges 
of 46% to 129%, 27% to 82%, and 15% to 81%, respectively. The high lipophilicity 
among synthetic cannabinoids was regarded as a crucial attribute for their poor 
recovery given their incomplete dissolution in the reconstitution solvent containing 
45% methanol. In addition, other researchers reported a poor recovery for synthetic 
cannabinoids in multi-analyte drug testing, concluding that achieving consistently 
high recoveries is difficult among compounds with diverse physicochemical 
properties [134]. A further increase in the methanolic content poorly affected the 
chromatographic peak shape of early eluting polar compounds. However, neither 
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the mass accuracy nor the mass resolving power was significantly affected by the 
addition of the urine matrix (Table 4). No instability for analytes kept in the 
autosampler for 13.5 h was observed, excluding two synthetic cannabinoids with a 
possible downward trend in their concentration. Thus, the method appears feasible 
for routine casework, since the screening results were in good agreement with 
confirmation analyses. Moreover, analysis of urine samples previously found 
positive for the synthetic cannabinoids JWH-018 and AM-2201 using an LC-MS/MS 
method [127] revealed a new metabolite, JWH-072-propanoic acid, first described 
by Lovett et al. [188]. Figure 4 illustrates the tentative identification of this major 
urinary metabolite of JWH-018, JWH-073, and AM-2201. In the MS and broadband 
MS spectra across the chromatographic peak of JWH-072-propanoic acid, the 
accurate masses of the precursor and product ions were found with a sufficient mass 




Figure 4. Tentative identification of JWH-072 propanoic acid in a urine sample (I). (A) Extracted 
ion chromatograms of the metabolites of synthetic cannabinoids, (B) nonselective MS full mass 
range spectrum, and (D) the broadband spectrum at the corresponding retention time for JWH-
072-propanoic acid. (C) The arrows represent the postulated fragmentation sites.
Automated post-acquisition data processing and reporting involved internal 
mass scale calibration for each sample, the generation and integration of extracted 
ion chromatograms followed by the retrieval of an average mass spectrum across the 
peak, a reverse database search with predefined tolerances for the mass and RT, and 
generating and printing a legible report of positive findings. Figure 5 provides an 
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example of a truncated urine sample results report. The software generates a user-
friendly report including the compound name, molecular formula, RT, and mass 
deviations from the reference values, isotopic pattern match (mSigma), precursor 
area, ion intensities (not shown), and mass resolving power. The colored lines 
indicate those compounds that fulfilled the predefined acceptance criteria. The first 
column lists the scores for the identification ranging from one to four. The presence 
of product ions (Q1 and Q2) and small deviations for the RT, mass, and mSigma 
resulted in a maximum score for an amphetamine. By contrast, the poor 
identification score for an alpha-PVP metabolite resulted from a lack of the 
corresponding reference standard. 
The time required for automated post-acquisition data processing and reporting 
was less than one minute per sample, followed by a few minutes to interpret the 
results report. The entire interpretation process involved a minimal degree of 
manual review. Occasionally, manual inspection of extracted ion chromatograms 
was necessary to rule out low-abundant positive findings caused by interfering 
matrix (III). In another DIA drug screening approach using an exact mass database 
search, a comparable amount of time was required for data interpretation, given 
that 48 blood samples took from 30 to 60 minutes to interpret [147]. However, in a 
DDA-based drug screening procedure, the post-run analysis involving database and 
library identification, manual exclusion of FP findings, and the report generation 
required 10 to 30 minutes per chromatogram [157]. A broadband DIA drug 
screening procedure, combining a post-targeted database search with a nontargeted 
workflow, required 5 to 30 minutes per blood sample [146]. The time requirement 




Figure 5. Truncated results report using the reverse database search with automated reporting 
and printing of positive drug findings from a drug user’s urine sample (II). Compounds with 
identification scores of four and three (green lines) represent compounds fulfilling the acceptance 
criteria with a minimum deviation for the mass (±1 mDa) and retention time (RT, ±0.1 min). 
Compounds with a score of two (yellow lines) indicated a greater but acceptable deviation for the 
mass (±2.5 mDa) or RT (±0.2 min). Compounds scoring one (white lines) indicated that the
identification is based on an accurate mass only.
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5.2 Performance comparison
The performance of UHPLC-HR-QTOFMS screening employing broadband DIA was 
compared to an immunoassay (III) and to the DDA mode applying the same 
instrument setup (II). This technique comparison was carried out in terms of the 
scope, flexibility, sensitivity, and reliability of identification based on the analysis of 
279 post-mortem (III) or 50 clinical (II) urine samples. 
5.2.1 Data-independent acquisition (DIA) vs immunoassay
Based on a comparison using established confirmation analyses, the screening 
results by immunoassay and broadband DIA were considered true positive (TP), 
false positive (FP), true negative (TN), or false negative (FN), from which the 
sensitivity (1) and specificity (2) were calculated using the following equations: 
(1) Sensitivity (%) = (TP/(TP+FN))×100 and 
(2) Specificity (%) = (TN/(TN+FP))×100. 
Table 5 shows the sensitivity and specificity values for those drugs included in 
the immunoassay panel. FN results from the immunoassay were primarily due to 
the method’s high cut-off limits. Amphetamines and opioids possessed the highest 
limits and, consequently, the lowest sensitivity values. FP results from the 
immunoassay were likely due to interfering matrix components. The highest 
number of FP were obtained for buprenorphine, resulting in the lowest specificity. 
Adjusting cut-off levels to lower concentrations than normally used would improve 
the sensitivity, but compromise the specificity [189]. By comparison, UHPLC-HR-
QTOFMS yielded one benzodiazepine FN due to detector saturation. This analysis 
was performed using the maxis Impact mass spectrometer, but the current Impact 
HD with an improved analog-to-digital converter would likely enable correct 
identification due to its wider dynamic range. Moreover, there were five FP using 
UHPLC-HR-QTOFMS for codeine and norcodeine, thus slightly diminishing the 
method’s specificity for opioids. In all of these cases, supposedly a cleavage of water 
(spontaneous fragmentation within the ion source) from the simultaneously 
occurring oxycodone metabolites gave rise to structures corresponding to these 
opioids. UHPLC-HR-QTOFMS revealed some additional drug findings of high 
toxicological relevance beyond the immunoassay drug panel. Such additional 
confirmed findings included both prescription drugs and NPS. 
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Several previous studies have suggested that LC-MS/MS could serve as an 
alternative to immunoassay [98,104,110]. In accordance with the results here, 
QTOFMS in particular appears more suitable for drug screening than immunoassay 
[90,145,147]. To date, however, no equally comprehensive evaluation substituting 
immunoassay using QTOFMS for urine drug screening exists beyond the present 
study (III). One study claimed the superiority of single-stage TOF-MS urine drug 
screening over immunoassay based on 800 authentic samples, but a lack of 
diagnostic product ions weakened its identification power [190]. 
Table 5. Cut-off concentrations and sensitivity and specificity values for UHPLC-HR-QTOFMS 
and immunoassay screening (III).













Amphetamines 6.5A 100.0 100.0 300.0 64.0 98.0 
Buprenorphine 1.0 100.0 100.0 1.0 89.0 96.0 
Benzodiazepines 15.0B 99.0 100.0 200.0 78.0 100.0 
Cannabis 15.0C 100.0 100.0 20.0 79.0 100.0 
Opioids 2.0D 100.0 98.0E 300.0 71.0 97.0 
Assigned for: A, methamphetamine; B, oxazepam; C, 11-nor-9-carboxy-Δ9-tetrahydrocannabinol; D, morphine; E, 
codeine. 
5.2.2 Data-independent acquisition (DIA) vs data-dependent 
acquisition (DDA)
In addition to nonselective broadband DIA with no quadrupole selectivity, another 
QTOFMS approach relies on collecting selective MS/MS data by DDA using preset 
criteria for the selection of precursor ions. A scheduled precursor list of 200 
compounds was used to trigger CID with compound-specific CE. While substance 
identification in DIA relied on a post-targeted reverse database search, the DDA 
method employed an in-house spectrum library search yielding scores for 
similarities between measured and reference mass spectra. Both the database 
employed in the broadband DIA mode and the spectrum library in the DDA mode 
comprised the same selection of 200 drugs. The performance evaluation of the 
acquisition modes for drug testing was performed on 20 model compounds using a 
single HR-QTOFMS instrument setup examining the sensitivity, specificity, spectral 
repeatability, and applicability to the casework. 
The selection of an appropriate acquisition mode depends on the purpose of the 
drug screening application. When investigating NPS use, prior knowledge is often 
missing. Therefore, approaches based on nontargeted data acquisition that produce 
the full mass range data on precursor and product ions are preferred. Yet, with 
pretargeted methods that enable quadrupole selectivity, qualitatively better product 
ion spectra are obtained. Studies that compare acquisition modes using a single 
instrument remain scarce. Applying the orbitrap technique, three acquisition 
approaches were compared for pesticide residue analysis: DDA, broadband DIA, 
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and a variable DIA that acquires mass data in segments similar to the SWATH 
technique [191]. Employing QTOFMS, two studies compared the toxicological 
screening performance between SWATH and DDA [192,193]. In drug discovery and 
development, SWATH, broadband DIA, and DDA were compared using a single 
QTOFMS-instrument [150,159]. However, prior to the present study (II), no 
comparison exists examining broadband DIA to a scheduled precursor list-type 
DDA drug screening technique using a single QTOFMS instrument setup. 
 
 
Figure 6. Number of drug identifications in 50 authentic urine samples using UHPLC-HR-
QTOFMS analyzed by data-independent (DIA) and data-dependent acquisition (DDA) modes for 
six drug groups (II).
Among 20 model drugs, 13 yielded a better LOI using DIA than DDA. Using DIA, 
an acceptable LOI was obtained for a majority of drugs, whereas using DDA a 
particularly high LOI (≥64 ng/mL) was observed for quetiapine, some 
benzodiazepines, and cannabis. Moreover, DIA proved superior in discriminating 
co-eluting isomeric compounds. Similar to other studies [192,193], DIA, comprising 
a wider range of different compounds, produced a higher number of drug 
identifications in authentic urine samples compared to DDA (Figure 6). Although 
DIA revealed a higher number of positive cases, DDA performed acceptably in 
screening for amphetamines, benzodiazepines, NPS, and prescription drugs. 
However, DDA appears unsuitable for screening for cannabis and opioids, and, in 
particular, buprenorphine. 
The reverse database search using DIA tolerated interferences caused by matrix 
and co-eluting compounds, while the spectral comparison of product ion spectra 
acquired using DDA appeared to depend more on spectrum purity. The library 
search relied on both a forward and reverse search. Applying only the reverse search 
protocol could work using DDA, since additional peaks from matrix and co-eluting 
compounds would be ignored in most cases when matching measured and library 
spectra. Figure 7 illustrates the identification of a synthetic cannabinoid (AB-
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FUBINACA) metabolite using both DIA and DDA. Although DDA yields cleaner 
spectra with appropriate fragmentation patterns, fewer matrix interferences, and 
excellent scores for the spectral match, substance identification using broadband 
DIA remains efficient despite the mixed spectra. The overall performance of post-
targeted broadband DIA drug screening appeared superior to pretargeted DDA 
enabling better sensitivity and applicability to casework, along with the flexibility 
required for the incorporation of emerging NPS. However, subsequently acquired 
DDA product ion spectra can be useful for occasional confirmation purposes. 
 
 
Figure 7. Identification of the AB-FUBINACA metabolite in urine using (A–B) data-independent 
acquisition (DIA) followed by a reverse database search and using (C–D) data-dependent
acquisition (DDA) followed by a spectrum library search (II). (A) Nonselective MS full mass range 
spectrum with a simulated theoretical spectrum for the precursor, (B) broadband sum spectrum 
with accurate masses for product ions at a corresponding retention time, (C) selective MS/MS 
spectrum measured with a preset collision energy, and (D) a library match with scores (%) for 
purity (P), forward fit (F), and reverse fit (R).
The MS-related definitions used throughout this thesis conformed to the 
recommendations by the International Union of Pure and Applied Chemistry 
(IUPAC) [118]. However, the definitions for forward and reverse library searches 
often rely on opposing meanings. One should always specify which definition is used 
when comparing procedures for a library search and the corresponding library 
scores for the spectral match. 
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5.3 Drug abuse patterns among drug users
In Finland in 2015, the top three drugs causing drug abusers to seek treatment 
consisted of opioids, stimulants, and cannabis [194]. Estimates suggest that only 
20% of problem opioid users attended medicinal opioid maintenance treatment in 
2012 [16]. Patients undergoing treatment in 2011 received a buprenorphine-
naloxone co-formulation (58%), methadone (38%), or buprenorphine alone (4%) for 
opioid dependence [195]. In a clinical toxicology setting, the commonly employed 
immunoassays remain incapable of detecting accurate drug use profiles, only 
providing drug class-specific results. Drug testing using comprehensive UHPLC-
HR-QTOFMS significantly contributes to the clinical assessment and treatment of 
drug users by providing toxicology results beyond the typical drug testing repertoire. 
The UHPLC-HR-QTOFMS screening was used to analyze samples acquired from 
two rehabilitation clinics supported either by a non-governmental organization (IV) 
or by a municipality (V), and from a harm reduction unit aimed at providing 
counseling for problematic drug users (IV). Samples were taken from subjects 
undergoing (V) or in queue for opioid maintenance treatment (IV and V), in drug 
withdrawal treatment (IV), suspected of acute intoxication (IV), and from untreated 
drug users with self-reported NPS abuse who irregularly visit a harm reduction unit 
(IV). The sample population in study (IV) primarily comprised drug abusers 
undergoing withdrawal treatment, while only a few received opioid maintenance 
treatment. Subjects receiving treatment visited rehabilitation clinics routinely, while 
anonymous subjects not attending drug dependence treatment merely received 
counseling on matters related to social services and health care from harm 
reduction unit. 
Subjects utilizing services provided by a non-governmental organization (IV) 
consisted of two groups: drug users attending treatment for drug dependence and 
subjects visiting a harm reduction unit receiving services other than medically 
supervised treatment. For the assessment of drug abuse the prescribed medicines 
reported by the subject or by the treating physician were excluded. In total, 79% of 
all analyzed samples were positive for abused drugs. Subjects not receiving 
treatment exhibited higher drug abuse rates than those receiving treatment (Figure 
8). However, similar rates of buprenorphine and benzodiazepine abuse appeared 
among both groups. Multiple substance abuse occurred in both groups of drug 
users, but was more pronounced among those not receiving treatment. In addition, 
the abuse of the prescription drugs pregabalin, gabapentin, and methadone always 
associated with other concurrently abused drugs. Likewise, NPS always appeared 
with other abused drugs. The number of concurrently abused substances by drug 
users attending and not attending treatment reached 2.1 and 3.9, respectively. The 
corresponding number for those with analytically confirmed NPS abuse was 
particularly high at 4.8 drugs. As illustrated in Figure 8, the typical pattern of drug 
abuse among those receiving treatment consisted of buprenorphine, 
benzodiazepine, and occasionally amphetamines. The abuse pattern among those 
not receiving treatment often included buprenorphine, amphetamine, cannabis, 
benzodiazepine, and alpha-PVP.  
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All subjects attending municipal opioid maintenance treatment (V) received 
either methadone (72%) or a buprenorphine-naloxone co-formulation (28%) as 
substitution for opioid dependence. A total of 46% of samples were positive for 
abused drugs, while over half of the samples tested positive for more than one 
abused drug. Among the positive samples, 26% showed signs of the simultaneous 
abuse of two drugs and 34% indicated that more than two drugs were 
simultaneously abused. Similar to subjects receiving treatment in study (IV), the 
mean number of concurrently abused drugs reached 2.1. Benzodiazepines 
represented the most commonly abused drug group, followed by amphetamines, 
cannabis, and NPS. Consistently in study (IV), alpha-PVP represented the most 
commonly found NPS while pregabalin was the most commonly abused prescription 
drug. Buprenorphine abuse appeared minimal (3%), indicating the success of opioid 
maintenance treatment (Figure 8). 
 
 
Figure 8. Drug abuse rates (%) for six drug groups and buprenorphine (separated from other 
opioids to emphasize its high abuse frequency) for subjects visiting a harm reduction unit (IV) and 
non-governmental (IV) or municipal (V) treatment facilities.
Drug users were often unaware which specific NPS they were abusing (V). In 
NPS-positive cases, the majority of subjects reported using only an amphetamine or 
the NPS MDPV. However, drug screening revealed the presence of NPS alpha-PVP, 
methiopropamine, and fluorinated designer amphetamines. Only one sample 
detected the same NPS that the individual reported using. This rather striking 
observation confirms that these results are in accordance with study (IV) as well as 
with the findings from a Swedish study. In that study, most of the self-reported 
MDPV abusers tested positive for alpha-PVP [182]. Again, the likelihood of 
detecting NPS increased with the increasing number of concurrently detected drugs, 
suggesting that NPS abuse frequently accompanies multiple substance abuse. 
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In study (V), multiple substance abuse was evaluated by dividing the positive 
drugs findings into six groups of abused substances: amphetamines, 
benzodiazepines, cannabis, opioids, NPS, and prescription drugs. In study (IV), in 
addition to the aforementioned substance groups, buprenorphine was separated 
from other opioids to emphasize its high abuse frequency. Thus, the number of 
concurrently abused drugs is not completely comparable between studies (IV) and 
(V). In a few cases from study (IV), the number of concurrently abused drugs 
diminished when more than one opioid was detected. 
The drug abuse patterns found in studies (IV) and (V) resemble those observed 
for fatal drug poisoning cases [2,167] and DUID studies [169-171] in Finland. In 
general, multiple substance abuse frequently occurs. Similar to the results from 
studies (IV) and (V), among fatal poisonings the most frequent NPS consisted of 
alpha-PVP and MDPV [2,167]. Moreover, the most frequent concurrently abused 
drugs among apprehended drivers included benzodiazepines and amphetamines, 
while buprenorphine was the main intoxicant in fatal poisonings. As exemplified by 
the high prevalence of alpha-PVP findings, this drug remains the NPS of choice in 
Finland despite becoming a scheduled narcotic substance in 2013. A similar trend 
was observed in Sweden, where alpha-PVP was widely abused for several years after 
scheduling [182]. Both in Sweden and Finland, the abuse of MDPV diminished after 
its scheduling in 2010 [172,181], which agrees with the low incidence encountered 
among drug users (IV and V). The observed high frequency of multiple substance 
abuse involving pregabalin agrees with other studies reporting significant 
pregabalin abuse combined with the use of other drugs [22,23]. While opioid 
maintenance treatment did not completely suppress the abuse of opioids (a 9% 
positive rate in study (V)), the range of abused drugs increased with a higher 
prevalence of multiple substance abuse among subjects not receiving substitution 




The ever-changing illicit drug scene compromises the feasibility of traditional drug 
testing. While suitable for high-volume drug screening within workplace drug 
testing, immunoassays cover only a fraction of the substances relevant to clinical 
and forensic toxicology. Such methods remain incapable of detecting most NPS and 
abused prescription drugs (III). Furthermore, they lack identification reliability due 
to FP and FN results and suffer from the risk of sample manipulation [196]. 
Therefore, immunoassays for comprehensive drug testing in forensic toxicology are 
inappropriate. 
In addition, analytical confirmation methods often lag behind the emergence of 
the newest NPS variants. Maintaining an extensive store of reference standards for 
NPS remains cost-inefficient due to such fluctuating analytical targets. The necessity 
of quantifying NPS has been questioned by a group of toxicologists, who list a 
multitude of issues concerning the measurement of NPS [38]. First, interpreting 
quantitative NPS results should be performed with great care. Information related 
to their toxicodynamics, stability, and post-mortem issues involving the 
redistribution and site sampling dependence remain inadequate. Moreover, the 
validation of quantitative methods is more laborious than that of qualitative 
approaches as required by accreditation agencies. Given these facts, the group 
suggested that the qualitative determination of NPS is sufficient for forensic 
purposes. Furthermore, it has been suggested that using the minimum required 
performance limit—that is, the lowest analyte concentration detected and 
confirmed—could provide results that are defensible in court [197]. 
The development of a multitarget drug screening method involves several 
analytical compromises allowing coverage of a wide range of analyte lipophilicities 
and differences in chromatographic behavior. An ideal screening method would also 
provide a wide dynamic range to detect drugs that may exhibit low concentrations 
or extremely high levels encountered in drug intoxications. All possible selectivity is 
required to avoid both FP and FN. This can be achieved using an efficient and 
generic sample preparation, optimizing UHPLC for resolution rather than speed, 
applying HRMS, and acquiring additional data on isotope and metabolite patterns 
and mass fragmentation. Generic sample preparation is useful, particularly within 
forensic toxicology, where typical clinical sample matrices such as plasma and urine 
are not always available. Montenarh et al. [97] described a single work-up procedure 
allowing for the detection of more than 100 drugs in eight matrices. In addition to 
urine samples, the drug testing procedure from study (I) applies to whole blood, 
vitreous humor [198], and hair [199] samples. 
HRMS screening provides substantial advantages compared to screening based 
on LRMS. Using HRMS, even co-eluting isomeric compounds can be identified 
without baseline separation (II), contrary to LRMS in which chromatography may 
play a more significant role. Even the formula-based tentative identification of 
unknowns becomes feasible based on an accurate mass at a high resolution (I), 
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although a reference standard is required for definitive confirmation. When the 
identification power of a drug screening method reaches the confirmation level, the 
former two-step practice of screening and confirmation can be diminished to a 
single step. Omitting that initial step saves time, labor, and expenses. HRMS enjoys 
a long history in science, involving sophisticated and expensive research 
instrumentation. Only recently, however, has TOF-MS technology reached a 
sufficiently high resolution to be considered an HRMS technique. HRMS performed 
with benchtop TOF-MS and orbitrap techniques is likely to become the gold 
standard for nontargeted screening owing to its flexibility, sensitivity, and selectivity 
[7,78,112]. 
The present method (I) relies on DIA with post-targeted data analysis allowing 
for the handling of moderate-sized datasets. Nontargeted data analysis handles 
larger and more complex mass spectral datasets. The inclusion of endogenous 
biomolecules, common impurities, and drug artifacts into the spectral library can be 
used to assist substance identification [111,135,200]. However, multiple 
sophisticated tools for processing unbiased data can be exploited to reduce the 
background noise and leave only that data most likely associated with the 
compounds of interest. Several noteworthy methodologies that simplify datasets 
include background noise subtraction [142,201], common fragment search 
[175,202], mass defect filtering [175,203], and the application of filters and in silico 
fragmentation matching [146]. A true nontargeted approach would identify 
unknown unknowns. Yet, even with the application of sophisticated tools for data 
processing, the nontargeted approach remains too laborious for routine casework. 
The DIA approach using the post-targeted database search presented in study (I) 
enables the identification of hundreds of known unknowns, with the possibility of 
nontargeted data mining in special cases. 
Clinicians would likely embrace a modern HRMS technique for drug testing, 
since it enables cost-effective analysis with a quick turnaround time. A multidrug 
screening method would facilitate optimal treatment for acute intoxications by 
reducing unnecessary supervision and costly treatments [204]. Comprehensive drug 
testing would enable discrimination between drug-induced psychosis and mental 
illness, for instance, when a young patient presents with new-onset psychosis or 
agitated delirium [32]. Knowing the exact drug would also assist the clinician by 
providing better information to the patient before discharge [71]. However, for now, 
the primary investigative tool for clinicians regarding NPS abuse remains patient 
self-reports [67]. 
The overall turnaround time of the present method (I) remains insufficient for 
emergency settings. Further adjustments involving automation and minimizing 
sample preparation are essential to reduce the manual workload. Various 
approaches for automated solid-phase extraction involve sample preparation on 
cartridges [134], 96-well plates [147,149], and in pipette tips [109]. Dilute and shoot 
methods involving no sample pretreatment can be applied to reduce analysis time 
[145,152,190]. An automated online extraction using turbulent flow chromatography 
could be employed to reach a better LOI than that achieved by dilution alone 
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[136,205]. The sensitivity, however, might remain inadequate for certain drugs of 
abuse occurring at low concentration levels [205]. 
Analytically confirmed epidemiological data on drug abuse in Finland remain 
scarce. The work in this thesis introduced a new tool for the detection of drug abuse, 
which can also be applied to extrapolate drug abuse patterns in the general 
population more reliably than through surveys alone. The typical Finnish drug user 
frequently abuses multiple substances predominantly consisting of prescription 
drugs, cannabis, and stimulants (IV and V). In addition, stimulant NPS (MDPV and 
alpha-PVP) are favored, increasing the risk of sympathomimetic toxidrome due to 
their additive effect when combined with other concomitantly abused stimulants. 
The low prevalence of synthetic cannabinoids in Finland may result from the 
popularity of homegrown marijuana resulting in an abundant supply of cannabis 
now approaching the European average [6,15,206]. Moreover, the absence of head 
shops typical in Central Europe may also contribute to the lack of synthetic 
cannabinoids on the Finnish drugs scene, which is fortunate, since the risk of a 
patient needing emergency medical treatment is 30 times higher than that 
accompanying natural cannabis [207]. NPS abuse is no longer restricted to 
experimental drug users such as clubbers and psychonauts. Instead, prisoners, 
people who self-medicate, or individuals seeking to improve their performance, as 
well as established drug users as also shown in studies (IV) and (V), now use NPS 
[4,5]. While NPS do not contribute to fatalities as much as conventionally abused 
drugs [2,167], they do carry serious public health risks due to the lack of past 
experiences upon which to rely. That is, information on their toxicity, interactions 
with other xenobiotics, and long-term health effects remain scarce. 
The NPS phenomenon requires constant vigilance from analytical toxicologists 
and health-care providers. In Finland currently, 16% of all deaths undergo a 
medico-legal cause of death investigation and 12% an all-encompassing toxicological 
analysis including drug screening by the new method (I) allowing for the 
straightforward recognition of new drugs [2]. The European Union early warning 
system disseminates information on the emergence and toxicity of NPS within 
Europe. For example, early warning system alerts on the emergence of new potent 
NPS opioids, such as U-47700, enabled the timely detection and subsequent 
reactions concerning these drugs in Finland [177]. One inspiring example of joint 
efforts stems from the Swedish STRIDA project, which produced valuable 
analytically confirmed information on NPS and their toxicity and symptoms for 
dissemination across the country [178,179]. Such co-operation encompasses a 
university laboratory, the poisons information center, and emergency departments 
across Sweden. Thus, collaboration among several authorities, including customs, 
police, law enforcement officials, emergency hospitals, poison centers, health 
departments, and drug testing laboratories facilitates the rapid identification of 
NPS, information exchange, law enforcement efforts, and optimal patient care. 
This thesis presents and assesses a comprehensive drug testing method with an 
equally high reliability as a dedicated target analysis. Identification relies on the 
broadband DIA approach involving an accurate mass of both precursor and product 
ions, retention time, precursor isotopic pattern, and reverse database search. 
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Confirmation analysis for positive results is unnecessary for health care purposes, 
although two separate analyses remain required in forensic cases [208]. In addition 
to routine drug screening within forensic toxicology, the new urine drug testing 
method appears well suited in treatment settings for drug abusers in Finland. 
Annually, thousands of patient samples are analyzed using this method, which 
received accreditation from the Finnish Accreditation Service. Since the 
introduction of the original method, corresponding methods have been introduced 
in Finland and elsewhere. The method (I) revealed approximately 100 different 
analytes in clinical case samples analyzed in 2015 by the Department of Forensic 
Medicine at the University of Helsinki. The most common drugs detected consisted 
of buprenorphine, benzodiazepines, cannabis, methadone, amphetamine, 
quetiapine, and gabapentinoids. Table 6 lists all those drugs detected in clinical 
samples in 2015 not prescribed as a part of normal medical treatment in Finland. 
Such a broad repertoire of drugs clearly indicates the need for a cost-effective testing 
method beyond the scope of immunoanalysis (III), as well as beyond the typical 
targeted LC-MS approaches (II). 
 
Table 6. Illicit drugs and metabolites detected in clinical case samples analyzed by the
Department of Forensic Medicine in 2015 using the UHPLC-HR-QTOFMS method (I) listed in 
order of decreasing prevalence.
    
1. 11-Nor-9-carboxy-Δ9-tetrahydrocannabinol (THC-COOH) 22. Phenmetrazine 
2. Amphetamine 23. Ethylone 
3. Alpha-pyrrolidinovalerophenone (alpha-PVP) 24. Lysergic acid diethylamide (LSD, metabolite) 
4. Methamphetamine  25. Para-methoxymethamphetamine (PMMA) 
5. Methylenedioxymethamphetamine (MDMA) 26. APINACA (5-hydroxypentyl metabolite) 
6. Methylenedioxyamphetamine (MDA) 27. Diphenidine 
7. Alpha-pyrrolidinoheptiophenone (PV8) 28. Methoxyphenidine 
8. AB-FUBINACA (carboxy metabolite) 29. Methylenedioxypyrovalerone (MDPV) 
9. Phenazepam (3-hydroxy metabolite) 30. 4-Methylethcathinone 
10. Lormetazepam 31. Mephedrone 
11. Flubromazolam 32. 5-(2-Ethylaminopropyl)benzofuran (5-EAPB) 
12. Benzoyl ecgonine 33. Bromazepam 
13. Etizolam 34. Dibutylone 
14. Cocaine 35. Fluorophenmetrazine 
15. Ecgonine methylester 36. Fluoromethamphetamine 
16. Methiopropamine 37. Hydrocodone 
17. Pyrazolam 38. Cocaethylene 
18. Flubromazepam (hydroxy metabolite) 39. Meta-chlorophenylpiperazine (mCPP) 
19. Isopropylphenidate 40. MDMB-CHMICA 
20. Ethylphenidate 41. Methoxetamine 





In general, the typical drug testing approach involves a two-step procedure to first 
screen using a quick and non-selective immunoassay followed by confirmation of 
the positive result using an MS-based method. Commercially available 
immunoassays and established confirmation methods, however, do not cover the 
entire range of abused drugs. In addition to typical illicit drugs, drug use today also 
comprises prescription drugs and NPS. In this thesis a comprehensive screening 
method was developed and validated, based on state-of-the-art UHPLC-HR-
QTOFMS instrumentation (I). 
 The primary components of this HRMS-based method’s success lies in both the 
acquisition of nontargeted DIA information and the reverse database search using 
advanced data processing. DIA carried substantial advantages over immunoassay 
(III) and over the DDA method employed using the same instrument (II) in terms 
of scope and sensitivity. Furthermore, data acquisition using nontargeted method 
could be exploited when searching for unknown drugs not included in the target 
database. Thus, this method enabled tentative identification of synthetic 
cannabinoid metabolites (I). In addition, the use of diagnostic product ions allowed 
for the identification of co-eluting isomers (II). Owing to the superiority of the 
developed method, it has largely replaced immunoassay drug screening for the 
treatment of people who abuse drugs in Finland. 
Furthermore, the method was used to assess the drug abuse patterns in various 
groups of drug abusers (IV and V). The primary drug findings among subjects not 
receiving treatment included buprenorphine, amphetamines, cannabis, 
benzodiazepines, and alpha-PVP (IV). The abuse pattern among subjects 
undergoing drug withdrawal treatment primarily included buprenorphine, 
benzodiazepine, and occasionally amphetamines (IV). The majority of subjects in 
opioid maintenance treatment received medicinal buprenorphine (V) and, 
therefore, appeared to abuse this drug to a lesser extent than subjects in study (IV). 
Both studies revealed a high frequency of multiple substance abuse. In particular, 
subjects not receiving treatment and those abusing NPS used multiple drugs (IV). 
The lower incidence of multiple substance abuse among subjects receiving 
treatment clearly showed the importance of drug withdrawal and opioid 
maintenance treatment in reducing multiple substance abuse. 
The comprehensive drug testing method used in this thesis appears feasible in 
forensic and clinical toxicology. In cause of death investigations, accurately 
identifying those drugs present in a post-mortem sample remains absolutely 
necessary. In clinical toxicology such detailed information regarding abused drugs is 
beneficial for the optimal treatment of drug users and in acute drug poisoning cases. 
A future challenge lies in developing an even simpler workflow for drug testing 
requiring minimal sample preparation and a short turnaround time. When these 
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